Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

427
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
427
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

473
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
473
Glaucoma: Overview01:25

Glaucoma: Overview

541
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
541
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

338
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
338
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An ECM-mimetic hydrogel for disc repair: reconstituting hypoxia and alleviating NPC senescence to halt intervertebral disc degeneration.

Journal of nanobiotechnology·2026
Same author

Neoadjuvant tislelizumab (anti-PD-1 antibody) plus chemotherapy in patients with advanced epithelial ovarian cancer: the exploratory NAIVE trial.

Signal transduction and targeted therapy·2026
Same author

An updated inventory of rock glaciers in the Eastern Himalaya.

Scientific data·2026
Same author

Proximal-distal coordination engineering of iron single-atom nanozyme for synergistic multi-enzymatic-photothermal control of antibiotic-resistant bacteria.

Journal of hazardous materials·2026
Same author

uPAR-Guided Dendrimer Gel Nanoparticles Reprogram Inflammation to Stabilize Atherosclerotic Plaques.

ACS applied materials & interfaces·2026
Same author

Comprehensive epidemiological analyses of urinary stone diseases in eastern China: a regional population-based study.

BMC public health·2026

Related Experiment Video

Updated: Jun 23, 2025

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

774

Consistent Intraocular Pressure Reduction by Solid Drug Nanoparticles in Fixed Combinations for Glaucoma Therapy.

Da Huang1,2, Pedro Norat3, Lin Qi2

  • 1College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian, 350108, China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|June 14, 2024
PubMed
Summary

A new scalable method creates solid drug nanoparticles (SDNs) for glaucoma. These brimonidine/betaxolol SDNs improve drug delivery and consistently lower intraocular pressure via eyedrops.

Keywords:
anti‐glaucoma drugscornea permeationocular hypertensionscalable fabricationsolid drug nanoparticles

More Related Videos

Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.2K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.0K

Related Experiment Videos

Last Updated: Jun 23, 2025

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

774
Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.2K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.0K

Area of Science:

  • Ophthalmology
  • Nanotechnology
  • Pharmaceutics

Background:

  • Topical drug delivery for glaucoma is challenging.
  • Nanoparticle formulations show promise but face hurdles like complex preparation and batch inconsistency.
  • Efficient delivery of combined antiglaucoma medications is needed.

Purpose of the Study:

  • To develop a scalable fabrication strategy for solid drug nanoparticles (SDNs) for enhanced topical glaucoma treatment.
  • To create uniform, fixed-combination brimonidine/betaxolol SDNs (BM/BX SDNs) with improved batch consistency.
  • To evaluate the efficacy and safety of BM/BX SDNs for glaucoma management.

Main Methods:

  • Fabrication of uniform fixed-combination BM/BX SDNs using a continuous process with trehalose as a lyoprotectant.
  • Assessment of reconstituted BM/BX SDNs for solution clarity, homogeneity, cytotoxicity, and irritation.
  • Evaluation of corneal permeation of BM/BX SDNs ex vivo and in vivo.
  • Measurement of intraocular pressure (IOP) lowering effects of BM/BX SDNs in normotensive rats and glaucoma mice.

Main Results:

  • A scalable continuous process yielded uniform BM/BX SDNs with good batch consistency.
  • Reconstituted BM/BX SDNs formed clear, homogenous solutions with negligible cytotoxicity and irritation.
  • BM/BX SDNs demonstrated significantly enhanced corneal permeation (2-3 fold) compared to hydrophilic drug counterparts.
  • Consistent IOP lowering effects were observed in both normotensive and glaucoma animal models.

Conclusions:

  • The developed scalable fabrication strategy is effective for producing stable, fixed-combination glaucoma drug nanoparticles.
  • BM/BX SDNs offer superior corneal penetration and consistent IOP reduction for topical glaucoma therapy.
  • This approach holds significant potential for improving glaucoma management through advanced eyedrop formulations.